FDA Approval, page-24

Plasmid,

My interpretation is the funds received for the sale of APAS will be split evenly, as the Robotics and Software will be part of the initial sale. Assuming split is even shown as dividend in the revenue drawing provided in my previous mail, less sales commission to distribution partner.
the going forward funds received for robotic maintenance will go to Hettich and software licensing fees and updates go to LBT. For me this will will be the cream with massive Long Term revenue stream generated. Believe analysts will be very interested in modelling this once accurate info on expected sales and license fees are made public.